Bath-based Somnus Scientific is aiming to make anaesthesia safer for patients, better for the environment and more cost effective for healthcare by unlocking alternatives to traditional gas-based anaesthetics.
Dr Tim Craft, co-founder and chief executive officer, Somnus Scientific, said: “The practice of keeping anaesthetised patients unconscious with gasses really hasn’t changed much in over 100 years, and 90% of operations worldwide are still performed using this technology.
“Anaesthetic gasses are heavily linked with nausea, slow recovery, memory loss and environmental damage, accounting for 5% of a typical hospital’s carbon footprint.”
Somnus’ solution is to aid the transition to the use of propofol as a drug for maintaining anaesthesia. Propofol is a short acting sedative that supports a recovery with very low incidences of nausea and patient confusion.
Dr Craft added: “Retrospective analysis indicates that patients who have cancer and are anaesthetised with propofol are more likely to be alive five years later than those given gaseous anaesthesia.”
Despite being first licensed for use in 1986, propofol has to date been primarily used as a drug for initiating anaesthesia, rather than a replacement for gases for its continuance. This has been largely due to the inability to accurately measure the levels of propofol concentration in a patient’s blood stream in real-time, and therefore monitor the extent and depth of the patient’s sedation during a procedure.
Somnus’ world-first biosensor aims to solve this problem. It uses enzymes to metabolise propofol, producing electrons that are measured at the sensor. Because the propofol has been removed by the enzyme, the sensor can be used repeatedly to allow continuous measurement of blood propofol concentrations. This allows anaesthetists to monitor and adapt sedation levels in real time.
The company is also producing an adapted sensor to be used in intensive care units, where propofol is frequently used to sedate patients who, for example, are being mechanically ventilated. This sensor will provide information on the concentration of propofol in the patient’s bloodstream and help to optimise the dosage of propofol given to each individual patient.
“There's now lots of research evidence indicating that a significant majority of patients in intensive care are over sedated, meaning they stay longer in the intensive care unit, they take longer to get off a ventilator, and most significantly, they are less likely to survive.”
Faster patient discharge also helps optimise intensive care resources. According to Statista, the UK had just 6.6 intensive care beds per 100,000 population at the onset of the pandemic, compared to 29.2 in Germany and 34.7 in the United States.
With support from Innovate UK EDGE Access to finance specialist, Ed Tellwright, Somnus Scientific recently raised £600,000 from a combination of private investors and a cornerstone institutional investor; Utilico Emerging Markets Trust plc.
“Ed really helped hone our pitching skills – we now focus on getting our ‘home runs in early’ grabbing the investor’s attention early on with our key selling points.”
The company will use the funds to further develop its products before undertaking testing in the UK. A phased domestic and international launch, focusing first on Europe and then on global markets will follow.
Dr Craft said: “The whole package of support from Innovate UK EDGE has opened doors that would have been very difficult to open by ourselves and it’s really helping us to accelerate towards commercialisation.”
